Clinical Trial

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 1, 2022 (before its estimated September 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes
Trial Details
NCT Number NCT05524974
Lead Sponsor Fujian Medical University
Conditions Locally Advanced Gastric Cancer
Enrollment 203 participants
Start Date 2022-09-01
Primary Completion 2024-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2022-09-01